# Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects

> **NCT01275157** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 6 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** LY2452473

## Key facts

- **NCT ID:** NCT01275157
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2011-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275157, "Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01275157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*